SurfWax News Index  |  Track News  |  Save/Exchange Information |  About Us News and Articles on Juvenile myoclonic Epilepsy Keppra XR(TM) Extended-Release Tablets Filed with the FDA  Jan 16, 2008 Important Safety Information Keppra(R) tablets and oral solution are indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy, myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy. Keppra(R) injection is indicated as adjunctive therapy... (PR Newswire) Damping the odds that fireworks will spark seizures  Jul 4, 2007 Among people with epilepsy, photosensitivity is most common in adolescents with a form known as juvenile myoclonic epilepsy. Anyone who begins to feel their body jerking while watching fireworks should cover both eyes immediately. (EurekAlert!) Key Approval for Keppra Offers New Treatment Option for Newly Diagnosed Epilepsy Patients  Aug 18, 2006 April 2006: Keppra(r) becomes the first newer AED approved in Europe for adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy (JME). August 2006: Keppra(r) injection (intravenous formulation) receives U.S. approval for use as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy. (Primezone Releases) Back to Health News [ Terms Of Use | Privacy | About ] ©1998-2008 SurfWax, Inc. All rights reserved. Patents pending. Copyright SurfWax, Inc. 2008